TR1801-ADC

N/A

Report date: 2024/02/05 13:58:04

Base Information

Drug NameTR1801-ADC

Drug Alias NameTR1801-antibody drug conjugateMT-8633TR1801-ADC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SG3199 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-Hepatocyte growth factor receptor

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTanabe Research Laboratories U.S.A. Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOpen Innovation Partners

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A